Compare Schwab US Large Cap Growth ETF (SCHG) vs 10X Genomics Inc (TXG) Price & Performance

SCHG trades at $35.25, down 0.79% today, with a bullish technical signal from moving averages and neutral oscillators. The ETF maintains strong institutional interest and offers exposure to large-cap growth stocks at a competitive expense ratio. Recent news highlights SCHG's historical outperformance versus the S&P 500 and ongoing comparisons with peers like QQQM and VUG.

Long-term growth potential remains supported by SCHG's track record, though concentration risk in top holdings and market volatility pose challenges. The ETF's low-cost structure and growth focus present opportunities for investors seeking diversified large-cap exposure, but requires monitoring of valuation levels and sector rotations.

TXG trades at $65.60, up 4.71% today, with strong technical momentum showing bullish moving averages and key support at $63. Fundamentally, the company demonstrates improving trends with Q2 2026 earnings beating estimates and revenue growth guidance raised, though profitability remains negative with a -12.18% net margin. Recent patent victory against Parse Biosciences strengthens competitive positioning.

The outlook remains cautiously optimistic with analyst consensus at 45% buy ratings and $50.78 price target. Key opportunities include Atera platform adoption and consumables growth, while risks center on valuation premiums and ongoing profitability challenges. The stock trades near resistance at $67 with institutional interest showing mixed signals.